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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer deaths in both men and
women in the United States (U.S. Cancer Statistics Working Group, 2013). In 2011, 51,783
people died from CRC (Centers for Disease Control and Prevention [CDC], 2014a). CRC can be
prevented by utilizing routine screening recommended by U.S. Preventive Service Task Force
(USPSTF, 2008). USPSTF (2008) recommends people with average-risk be screened for CRC
at age 50 years and older. Current low CRC screening rate at 64.5% in 2010 (CDC, 2013a)
indicates that many more Americans will be diagnosed with CRC in the future. Researchers
studying the causes of low participation in CRC screening have recognized that there are barriers
related to use of invasive test methods (flexible sigmoidoscopy and colonoscopy) such as
uninsured status, and lack of providers’ recommendation. Fecal occult blood test (FOBT) such
as high-sensitivity FOBT or fecal immunochemical test (FIT) is one of the recommended tests by
USPSTF. A low sensitivity of gFOBT for detecting polyps and CRC is considered to be a major
barrier in its utilization which is low at 10.4% as a screening modality (CDC, 2013b).
In an effort to increase CRC screening rates, to improve utilization of FOBT may be
worth investigating. The initial focus of this DNP practice inquiry project was to examine the
efficacy of FOBT and if utilization of FOBT will be a reliable test methods in detecting polyps
or CRC. The first manuscript is a literature review of studies published between 2008 and 2015
that focused on the efficacy of FOBTs in people aged 50 years and older. During this review,
FOBT was recognized as optimal alternative tests for those who are reluctant to undergo an
invasive method for CRC screening although the efficacy of FIT is not as high as the efficacy of
colonoscopy. With the findings from the literature review, the next step of this project was to
identify a strategy that can promote increasing the utilization of FOBT. The second manuscript
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evaluates an innovative program known as FluFOBT program to examine the potential impacts
on improving CRC screening rates among low-income eligible adults. Findings from conducting
an evaluation of the program showed its effectiveness in increasing CRC screening rates and
having significant cost benefits. These findings led to curiosity about what advanced practice
registered nurses (APRN) know of the current CRC screening recommendation guidelines and
their attitude toward making a referral for CRC screening. The final manuscript focuses on
examining the relationship between the APRN knowledge level of the current CRC screening
recommendation guidelines and their self-reported referral rates of CRC screening by conducting
online survey via Kentucky Coalition of Nurse Practitioners and Nurse Midwives listserv.
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Manuscript # 1:
Efficacy of Fecal Occult Blood Test: A Literature Review
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Abstract
Colorectal Cancer (CRC) is the second leading cause of cancer deaths in both men and
women in the United States. In 2011, 51,783 people including 26,804 men and 24,979 women
died in 2011. Evidence-based CRC screening guidelines by U.S. Preventive Service Task Force
(USPSTF, 2008) recommend a high-sensitivity fecal occult blood test (guaiac FOBT) and fecal
immunochemical test (FIT) annually, but the utilization of both tests is low at 10.4%. Offering
non-invasive methods to those who are reluctant to participate in CRC screening may be worth
investigating. The purpose of this review of literature is to describe the efficacy of FOBT
(guaiac-based FOBT [gFOBT] & fecal immunochemical test [FIT]) in screening CRC. Findings
showed that FIT compared with gFOBT is superior in detecting CRC and advanced neoplasia
and participating rates.
Keywords: colorectal cancer screening, screening modalities, fecal occult blood test,
fecal immunochemical test, efficacy, fecal occult blood test randomized controlled trial, and
fecal occult blood test systemic review.

5

Efficacy Fecal Occult Blood Test:
A Literature Review
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer deaths in both men and
women in the United States (U.S. Cancer Statistics Working Group, 2013). Although CRC
deaths have been declining over the past two decades, 51,783 people including 26,804 men and
24,979 women died in 2011(Centers for Disease Control and Prevention [CDC], 2014) and
nearly 50,310 were projected to die from it in 2014 (American Cancer Society [ACS], 2014a;
Siegel, DeSantis, & Jemal, 2014). The incidence rates of CRC also have been decreasing by an
average of 3.4% yearly over the past 10 years (Siegel et al., 2014). Regardless, 135,260 people
were diagnosed with CRC in 2011 (CDC, 2014) and nearly136, 000 were expected to be
diagnosed with CRC in 2014(Siegel et al., 2014). Incidence and death of CRC can be
substantially reduced when recommended screening tests by U.S. Preventative Service Task
Force (USPSTF, 2008) are properly utilized for eligible adults. Regrettably, the low CRC
screening rate at 64.5% in 2010 (CDC, 2013a) indicates that many more American will be
diagnosed with CRC in the future.
Research suggests that one barrier for CRC screening may be use of invasive methods
such as sigmoidoscopy and colonoscopy. Offering non-invasive methods to those who are
reluctant to participate in CRC screening may be worth investigating. The purpose of this review
of literature is to describe efficacy of FOBT in screening CRC.
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Background
Detecting polyps or CRC at an early stage can be challenging as, generally, there are no
apparent signs and symptoms. Even when CRC advances, the nonspecific nature of
gastrointestinal symptoms makes it difficult to recognize CRC without appropriate tests. These
nonspecific gastrointestinal symptoms include abdominal pain, rectal bleeding, anemia,
unintended weight loss, and alteration in bowel habits (Jednak & Nostrant, 1998; Tomlinson,
Wong, Au, & Schiller, 2012). CRC screening guidelines from USPSTF (2008) recommends
people with average-risk (i.e. those who have no family history of colorectal neoplasia) be
screened for CRC at age 50 years and older. Currently, there are several tests detecting CRC
including sigmoidoscopy, standard colonoscopy, virtual (CT) colonoscopy, double contrast
barium enema, fecal occult blood tests (FOBT) and stool DNA, (ACS, 2014b; National Cancer
Institute[NCI], 2014a). The USPSTF CRC screening guidelines recommend utilization of the
following three tests; high-sensitivity fecal occult blood test (FOBT) including fecal
immunochemical test (FIT), sigmoidoscopy with FOBT, and colonoscopy (USPSTF, 2008).
According to USPSTF CRC screening recommendations guidelines, high sensitivity FOBT or
FIT (annually), sigmoidoscopy with FOBT (every 5 years with every 3 years), and colonoscopy
(every 10 years) are recommended for adults with average risk (USPSTF, 2008). A colonoscopy
is recommended as a follow-up test for people with abnormal findings as it is considered the gold
standard procedure for making a diagnosis and preventing CRC by many expert medical groups.
Although effectiveness of these modalities in detecting polyps or CRC has been
demonstrated in numerous studies, current low CRC screening rates indicate an under-utilization
of these tests. Willingness to undergo a CRC screening test may be an important step for the
eligible adults. Researchers studying the causes of low participation in CRC screening have
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recognized that there are barriers related to the tests that use invasive methods. In an effort to
increase CRC screening rates, offering non-invasive methods to those who are reluctant to
participate in CRC screening may be worth investigating. FOBT and FIT are both non-invasive
methods recommended as screening tests by USPSTF, but the utilization of them are low at 10.4%
(CDC, 2013b). Both high- sensitivity FOBT and FIT examine feces to detect occult blood and
can be done at a user’s convenience at his or her home. This may be an applicable choice for
those who are unwilling to undergo colonoscopy or sigmoidoscopy.
FOBT was introduced around 1970 and has been evolving since then (Schapiro, 2007).
FOBT detects hidden blood products in stool by using chemical guaiac. The concept of
detecting occult blood in stool by using guaiac gum was credited to Van Deen in 1864 (Simon,
1985). This principle is based on the idea that the fragile blood vessels at the surface of enlarged
polyps and CRC are easily damaged by the passing feces (ACS, 2014b). FOBT is divided into
two groups; guaiac-based (gFOBT) and immunochemical (iFOBT or FIT). The earlier method
known as gFOBT relies on detecting heme, the pigment-producing component of hemoglobin
(Young, St. John, Rose, & Blake, 1990; Young, 2004). A reaction between heme and a 3-6%
hydrogen peroxide developer in ethanol or methanol results in oxidation of guaiac causing the
appearance of a blue color (Carroll, Seaman, & Halloran, 2014). GFOBT requires moderate
amount of heme in order to produce the appearance of blue color, (Young et al., 2014). However,
consumption of certain foods such as meat products, peroxide-rich fruits, and vegetables can
influence the test result (Sinatra, St. John, & Young, 1999). Plant peroxides that are
hemoproteins and bloods from meat products react with the hydrogen peroxide developer and
produce oxidation of guaiac that may lead to a false positive test result (Sinatra et al., 1999;
Young et al., 2014). Since heme from animal blood is similar to heme from human blood,
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gFOBT cannot distinguish them apart (Young et al., 2014). Antioxidants also disrupt the
chemical reaction between heme and the hydrogen peroxide developer, and can lead to a false
negative test result (Young, 2004).
FIT also examines blood in feces by utilizing antibodies rising against the globin portion
of human hemoglobin. Globin is specific to species, thus the test result is less likely affected by
the influence of hemoglobin from dietary resources and diet restriction prior to the FIT is
unnecessary (Carroll et al., 2014). Human hemoglobin in stool binds to antibodies when it is
mixed with the reaction mixture and gathers the complexes form of globin (Carroll et al., 2014).
As a result, the fecal sample becomes turbid that can be measured by a turbidimeter (Carroll et
al., 2014). A higher rate of the turbidity indicates higher human hemoglobin concentration in
feces (Carroll et al., 2014). Globin in feces suggests bleeding from lower gastrointestinal (GI)
tract such as the colon or rectum because globin from the upper GI tract including mouth,
pharynx, esophagus, stomach, and duodenum are rapidly degraded while passing through the
path of upper GI tract (Enterix Inc, 2013; Smith, Young, Cole, & Bampton, 2006).
The earlier gFOBT demonstrated a low sensitivity for detecting CRC (Imperiale,
Ransohoff, Itzkowitz, Turnbull, & Ross, 2004), and thus was problematic as a modality for CRC
screening. Rehydrating the stool samples has improved sensitivity, and newer gFOBT such as
Hemoccult II Sensa were developed to improve sensitivity (Smith et al., 2006). Commonly used
gFOBT tests require three stool samples ideally taken at three different times (Washington State
Department of Health, 2010). GFOBT cards have three sections with two windows on each
section. Patients are instructed to smear stool from two different parts of the sample in each
window for three separate stool samples. After completion of all three sections, the gFOBT card
needs to be sent to a laboratory or health care facility for analysis. Although most FITs continue
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to use a similar sampling technique with gFOBT, sampling methods have been evolving with
FIT. A brush-based sampling method is a new- comer that requires for a user to swish the brush
at the surface of the toilet bowel water after the stool is immersed (Young, 2004).
InSure®FIT™, one of the new-comers using the brush technique, has two flaps where the
swished brush will be dabbed (Enterix Inc, 2013). Two flaps require separate stool samples in
order to improve detection of blood (Enterix Inc, 2013). After completion, the test is sent to
designated laboratory for analysis.
Convenience and acceptability combined with ease and simplicity in stool sampling are
characteristics for the ideal FOBT (Young, 2004). Researchers conducted a randomized cohort
trial among urban residents aged between 50 and 69 years in Adelaide, Australia comparing
participation rates among three groups; the Hemoccult SENSA (gFOBT) requiring three stool
samplings using a spatula and the restriction of certain foods and drugs; FlexSure OBT (FIT)
requiring three stool samplings using a spatula and no food and drug restriction; and
InSure®FIT™ (FIT) requiring two samplings using a brush (Cole, Young, Esterman, Cadd, &
Morcom, 2003). Cole et al. (2003) identified the highest participation in the group using
InSure®FIT™ with 39.6% while the group using FlexSure had a participation rate of 30.5%.
The group using the Hemoccult SENSA was the lowest at 23.4% in participation. This study
demonstrated that convenience and acceptability play a vital role for people in determining
whether or not to participate in CRC screening.
Large randomized controlled trials in Europe have also validated that FOBT can reduce
CRC mortality (Bosetti et al., 2011; Hardcastle et al., 1996; Mandel et al., 2000). In order to be
successful, a screening test must have several characteristic, including eligible individual’s
willingness to participate, convenience to the test, and the essential sensitivity/specificity of the
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test (Young et al., 2014). Sensitivity and specificity of FOBT also must be compatible compared
with other modalities such as colonoscopy and sigmoidoscopy.
Methods
Electronic databases including the Cumulative Index to Nursing and Allied Health
Literature (CINAHL), EBSCOhost, Pubmed, ScienceDirect, Cochrane Systematic Review, and
Google Scholar were searched using the keywords colorectal cancer screening, screening
modalities, fecal occult blood test, fecal immunochemical test, efficacy, fecal occult blood test
randomized controlled trial, and fecal occult blood test systemic review. Inclusion criteria
consisted of articles published between 2008 and 2015 that focused on the efficacy of FOBTs
(gFOBT and FIT) in people aged 50 years and older. In order to assess the applicability of
articles to the study, article titles and abstracts were initially reviewed. If titles and abstracts
were not sufficient in providing eligibility, the entire article was reviewed.
Search Results
Twelve studies met the inclusion criteria. Three studies were randomized controlled
trials (RCT) including Hol et al. (2009), Lindholm, Brevinge, and Haglind (2008), and Quintero
et al. (2012). Cochrane Systematic Review included one study by Hewitson, Glasziou, Watson,
Towler, and Irwig (2008). The remaining eight studies consisted of observational studies;
Grazzini et al. (2009), Parra-Blanco et al. (2010), Kershenbaum, Flugelman, Lejbkowicz, Arad,
and Rennert (2012), Ou et al. (2013), Shin et al. (2012), Parente et al. (2014), Quintero et al.
(2014), and Turenhout et al. (2014). The sample size for three RCT studies ranged from 15,011
to 68,308. The Cochrane Systematic Review examined nine articles describing four RCTs
consisting of more than 320,000 participants in a period of 8 to 18 years. Sample size for nine
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observational studies ranged from 1,918 to 325, 881. Shin et al. (2012) did not specify the
number of participants but described the total number of tests performed.
Researchers studied the effects of utilizing FOBTs as a CRC screening modality on the
outcomes of performances in CRC detection rates and/or participation in CRC screening
(Grazzini et al., 2009; Hol et al., 2009; Kershenbaum et al., 2012; Ou et al., 2013; Parra-Blanco
et al., 2010; Quintero et al., 2012; Quintero et al., 2014; Shin et al., 2013; Turenhout et al., 2014)
and reduction in CRC incidence and/or mortality (Hewitson et al., 2008; Lindholm et al., 2008;
Parente et al., 2014). Other outcomes included cost effectiveness (Parente et al., 2014) and
occurrence of major complications (Quintero et al., 2012).
Key Findings
CRC & Advanced Neoplasia Detection
Most studies focused on FOBTs efficacy in detecting CRC and advanced neoplasia,
including an adenoma ≥ 10.0mm, villous adenoma, and early stage cancer based on the NCI
definition (NCI, 2014b). When discussing the efficacy of a screening test, sensitivity, specificity,
positive predictive values (PPV), and negative predictive values (NPV) are commonly used
values. Sensitivity refers to the ability of a test to detect diseased individuals correctly, while
specificity is defined as an ability of the test to identify disease-free individuals correctly (Parikh,
Mathai, Parikh, Sekhar, & Thomas, 2008). The probability of having a disease with a positive
result is known as PPV, while NPV is probability of not having a disease with a negative test
result (Parikh et al., 2008).
The majority of studies reviewed agreed on the superior efficacy of FIT compared with
the efficacy of gFOBT in detecting advanced neoplasia and CRC (Hewitson et al., 2008;
Grazzini et al., 2009; Ou et al., 2013; Parra-Blanco et al., 2009; Shin et al., 2013). Sensitivities

12

of FIT and gFOBT were 61% versus 23.8% respectively in detecting significant neoplasia with
food intake restrictions including red meats, vegetables, and vitamin C for three days prior to
stool sampling (Parra-Blanco et al., 2009). Hewitson et al. (2008) found the sensitivity of
gFOBT as ranging from 55% to 57% compared with the sensitivity of high-sensitive gFOBT
ranging from 82% to 92%. Screening with high sensitivity gFOBT annually also demonstrated
achieving high rates of cancer detection (Kershenbaum et al., 2012; Parra-Blanco et al., 2010).
For example, Kershenbaum et al. (2012) found that annual Hemoccult Sensa (gFOBT) was
achieving high success in detecting CRC by about 84-93% of expected CRC occurrence in
Jewish populations aged 50-64 years and 90-99% for Jewish populations aged 65-74 years.
Interestingly, Shin et al. (2013) and Turenhout et al. (2014) recognized a difference in
sensitivity of the FIT between in men and women. For instance, males had higher sensitivity
by13% to 23% than females at all cut-off values; 50ng/ml, 75ng/ml, 100ng/ml, and 200ng/ml
(Turenhout et al., 2014). Shin et al. (2013) reported smaller difference (5.87%) of sensitivity
between men and women. Two studies (Castiglione, et al., 2007; Malila, Oivanen, Malminiemi,
& Hakama, 2008) in Europe also reported similar findings of higher sensitivity of FIT in men
than in women.
Parra-Blanco et al. (2009) found that PPV of FIT was 43.4% while PPV of gFOBT was
39.0%. Parra-Blanco et al., (2009) also learned that NPV of FIT was 97.5% and NPV of FOBT
was 95.4%. Hol et al. (2010) reported similar results with findings from Parra-Blanco et al.,
(2009).
Reducing CRC Incidence and Mortality
Large RCTs (Bosetti et al., 2011; Hardcastle et al., 1996; Mandel et al., 2000) in Europe
have demonstrated the effectiveness of gFOBT in reducing CRC mortality. Several studies
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showed similar results (Hewitson et al., 2008; Lindholm et al., 2008; Parente et al., 2014).
Hewitson et al. (2008) concluded that combining the annual and biennial screening with FOBT
reduced CRC mortality by 16% from conducting Cochrane systemic review of four RCTs. A
study in Sweden for Goteborg citizens aged 60 to 64 years with high-sensitivity gFOBT
following restrictions on foods (red meats, peroxidase-rich fruits and vegetables) and medicines
(iron supplements and vitamin C) for two days prior to collecting stool samples, also showed a
similar reduction rate of 16% in CRC mortality (Lindholm et al., 2008). However, the incidence
of CRC or overall mortality rate of CRC after 19 years from the start of the trial showed no
difference between the screened and controlled groups (Lindholm et al., 2008). Utilizing
rehydrated gFOBT (high sensitivity FOBT) two to three times for CRC screening appears to
facilitate reducing CRC mortality. Parente et al. (2014) also demonstrated 5-years mortality
considerably reduced (19%) in screening group (19%) with a single FIT compared with nonscreening group (37%) or pre-screening group (41%).
Participation Rate
Utilization of FOBT seems to facilitate improved CRC screening rates among eligible
adults who are reluctant to undergo invasive screening tests (i.e. flexible sigmoidoscopy &
colonoscopy). FIT (61.5%) showed higher participation rates than gFOBT (49.5%) or flexible
sigmoidoscopy (32.5%) (Hol et al., 2010). Quintero et al., (2012) also found similar results with
a participation rate 34.2% for FOBT and 24.6% for colonoscopy (Quintero et al., 2012). Parente
et al. (2014) found overall acceptance of FIT was 50%. However, some have found that women
have higher participation rates in screening with gFOBT or FIT compared with men (Hol et al.,
2010; Parra-Blanco et al., 2009).
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Strategies and Cut-Off Values
Two types of FOBT were evaluated in the studies reviewed; gFOBT and FIT. FIT
consisted of two types; qualitative testing for positive or negative for blood in feces (qlFIT) and
quantitative measuring hemoglobin content in feces (qnFIT). GFOBT was studied by Hol et al.
(2009), Kershenbaum et al. (2012), Lindholm et al. (2008), Ou et al. (2013), and Parra-Blanco et
al. (2010). Quantitative FIT was studied by Grazzini et al. (2009), Hol et al. (2009), Parente et al.
(2014), Parra-Blanco et al. (2010), Quintero et al. (2012), Quintero et al. (2014), and Turenhout
et al. (2014). Both quantitative and qualitative FIT was studied by Ou et al. (2013) and Shin et al.
(2013) while FIT and gFOBT were examined by Ou et al. (2013) and Parra-Blanco et al. (2010).
Ou et al. (2013) argued that FIT performance was determined by the cut-off values of
hemoglobin in feces ranging from 25 to150 ng/mL. Three studies by Grazzini et al. (2009), Ou
et al. (2013), and Turenhout et al. (2014) evaluated FOBT performances at different cut-off
values of hemoglobin levels in feces. One study found that males had a higher sensitivity for
CRC than females at all cut-off values, including 50ng/ml, 75ng/ml, 100ng/ml, and 200ng/ml
(Turenhout et al., 2014). For example, the sensitivity of FIT for CRC at 75ng/ml was
considerably higher (93%) in males compared with females (71%). On the other hand, FIT
sensitivity for advanced adenomas demonstrated no significant difference for males and females.
A study identified that biennial one-time FIT with a cut-off value of 100ng/ml had a higher
detection rate for CRC and advanced adenoma than gFOBT (Grazzini et al., 2009), while another
study reported that hemoglobin concentration in feces was increased in participants who had
polyps bigger than 10mm or advanced adenomas (Ou et al., 2013). Repeated FIT screening with
a cut-off value at 50ng/ml annually for three consecutive years demonstrated its compatibility to
colonoscopy in CRC screening (Quintero et al., 2014). Repeated FIT has been found to
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substantially decrease the need for follow-up screening with colonoscopy by 2-4 folds (ParraBlanco et al., 2009; Quintero et al., 2014).
Utilizing different strategies of FOBTs seems to influence their performances. Strategies
can involve sampling frequency, cut-off values of hemoglobin level I feces, and restriction of
diet and medicines. Employing an annual high sensitivity gFOBT (Kershenbaum et al., 2012;
Parra-Blanco et al., 2010), a single fecal sample with FIT (Hol et al., 2009; Shin et al., 2013) one
time, every two years (Grazzini et al., 2009; Parente et al., 2014; Quintero et al., 2012), or every
year for 3 consecutive years (Quintero et al., 2014) were examined in studies. Some researchers
asked participants receiving gFOBT to follow restriction of diet and medicines two to three days
prior to stool sampling (Lindholm et al., 2008; Parra-Blanco et al., 2010; Kershenbaum et al.,
2012). In addition, cut-off values of hemoglobin in feces were used at different levels; 50ng/ml
(Ou et al., 2013; Parra-Blanco et al., 2010; Quintero et al., 2014; Turenhout et al., 2014; ), 7579ng/ml (Grazzini et al., 2009; Quintero et al., 2012; Turenhout et al., 2014), and 100ng/ml (Hol
et al., 2010; Parente et al., 2014).
Staging Distribution and Location
Stage distribution of a cancer is considered a strong predictor for the 5-year survival rates
commonly used in determining cancer outcomes (ACS, 2014b). In other words, detecting CRC
at early stages significantly increases 5-year survival rate. Parente et al. (2014) found that
overall 5-year survival rate was increased to 81.1 percent in screening group compared with nonscreening group (63%) or pre-screening groups (58.9%). CRC detection at stage 1 was 54.7% in
the screening group while only 10% for the non-screening group and 15.8% for the pre-screening
group. Stage distribution also markedly differed between the screening group and non-screening
group (Parente et al., 2014). Kershenbaum et al. (2012) also identified that 70% of the cancer
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detected among the Jewish population was at stages Duke’s B and lower, meaning that the
cancer invades only through the muscle layer (NCI, 2014c).
FIT and gFOBT exhibited differences in detecting advanced neoplasia depending on
location. According to the study by Parra-Blanco et al. (2010), advanced neoplasia at proximal
location was often found by FIT. Comparing the stage distribution of left and right-sided colon
cancer, right-sided colon cancers were detected lower and in relatively advanced stages
(Kershenbaum et al., 2012). Findings by Shin et al. (2013) also indicated that the FIT showed
the highest sensitivity for the left and sigmoid colon at 87.9%, with the above finding by
Kershenbaum et al. (2012). In addition, Shin et al. (2013) found that the sensitivity of FIT was
highest for distal colon cancer at 65.9% and rectal cancer at 58.4% compared with proximal
colon cancer. However, Quintero et al. (2012) reported that there was no significant difference
between FIT and colonoscopy in detecting CRC based on location.
Cost effectiveness
CRC screening appears to be cost effective. FOBT reduced CRC incidence by detecting
polyps or CRC at early stage which cost considerably less in treatment compared with the cost of
advanced CRC. A study in the Lecco province of Italy by Parente et al. (2014) found the mean
total cost for first year diagnosis were €16,435 ($18,571 based on the current money value),
€20,862 ($23,574), €29,845($33,725), and €37,288($42,135) for stage I, II, III, and IV
respectively.
Complications
One study by Quintero et al. (2012) described 0.5% of participants experienced some
form of complication from undergoing a colonoscopy. These complications included bleeding in
12 participants, hypotension or bradycardia in 10 participants, desaturation in 1 participant, and
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bowel perforation in 1 participant. On the other hand, only 0.1% of participants in FIT group
experienced bleeding, hypotension, or bradycardia. However, the complications in FIT group
were related to colonoscopy as a follow up test after the participants had a positive result with
FIT.
Discussion
Critique of Studies
Employing FIT compared with gFOBT was associated with a higher participation rate
and superior efficacy in detecting advanced neoplasia and CRC, particularly in men. FIT was
compatible with a colonoscopy in CRC screening when a cut-off value of 50ng/ml annually was
repeatedly used for three consecutive years. FOBT has two types; gFOBT and FIT, which is also
divided into qualitative test and quantitative test. Quantitative tests reviewed were measured
with several cut-off values of hemoglobin in feces which influenced the performance of FIT.
FOBT was also cost effective with few complications. Other interesting findings include the
followings; higher FIT sensitivity for CRC in males than in females with all cut-off values,
differences between gFOBT and FIT in detecting advanced neoplasia depending on the location
of the CRC, and differences in finding CRC at stage distribution with FOBT between screening
and non-screening groups.
Limitations
Eight of twelve studies were observational. A limitation related to an observational study
is its inability to show causal relationships between interventions and outcomes (Polit & Beck,
2010). Thus, the effect of employing FOBT for the reduction in CRC incidence and mortality
rate cannot be fully established. Another limitation of an observational study is related to its
strength of evidence, which is inferior compared with RCTs. This results in weakening the
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strength of the findings from these studies. Other limitations are related to inconsistency in
utilization of FOBT. For instance, reviewed studies used different cut-off values of hemoglobin
in feces (25ng/ml, 50ng/ml, 75ng/ml, 100ng/ml, 125ng/ml, and 200ng/ml), different types (high
sensitivity gFOBT, qualitative FIT, and quantitative FIT), and different frequency (annual versus
biennial). These differences limit reasonable comparison of outcomes.
Implications for Practice
Improving CRC screening rates among eligible adults is critical. Findings from reviewed
studies support the utilization of annual FIT for CRC screening as currently recommended by
USPSTF. Although the efficacy of FIT is not as high as the efficacy of colonoscopy, providers
must understand that FIT has demonstrated significant improvement in its ability to detect
advanced neoplasia and CRC recently. As a result, they should offer FIT for those who are
hesitant to undergo colonoscopy or unable to be screened with colonoscopy due to their low
socioeconomic status.
Conclusion
A low sensitivity of gFOBT for detecting polyps and CRC is considered to be a major
barrier in its utilization as a recommended screening modality by USPSTF. FIT compared with
gFOBT demonstrated superiority in detecting CRC and advanced neoplasia and participation to
screening. In consequence, FIT may be a reasonable test that can be accepted by a broad range
of populations. Further research needs to be conducted to determine the most effective cut-off
value of hemoglobin that is most effective in detecting polys and CRC. The USPSTF
recommendations guidelines for CRC screening in 2008 will be up-dated in the near future. The
research findings provided vital evidences that should be considered in up-dating recommended
screening modalities for CRC screening.
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Abstract
The purposes: To explore, provide a framework for implementing the Influenza Shot and Home
Testing Kit for FOBT program (FluFOBT), and conduct a cost benefit analysis of the program.
Methods: A cost benefit analysis of the FluFOBT program was conducted to estimate the cost
of implementing this innovation based on the information provided in implementing the same
program at the China town Public Health Center.
Results: A cost-benefit analysis showed a cost-savings per person of $11,810 for men and
$12,445 for women. With those cost savings, the 1-4 FluFOBT programs can be implemented.
Each program is capable of screening 75-100 eligible adults.
Conclusion: The FluFOBT program appears to be effective not only in improving CRC
screening rates but also in saving costs. Implementing the FluFOBT program seems to be a
promising way to reach both those of low socioeconomic status and racial/ethnic minorities. The
FluFOBT program should be used as an optional program that serves for many eligible adults
with inexpensive costs.
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Introduction
Colorectal Cancer (CRC) can be a prevented disease by utilizing routine screening
recommended by U.S. Preventive Service Task Force (USPSTF, 2008). In 2011, 51,783 people
died from CRC (Centers for Disease Control and Prevention [CDC], 2014a). For adults aged 5075 years with average- risk, the USPSTF CRC screening guidelines recommend using any of the
following modalities; fecal occult blood test (FOBT) such as high-sensitivity FOBT or fecal
immunochemical test (FIT) annually, sigmoidoscopy every 5 years with FOBT every 3 years,
and colonoscopy every 10 years (USPSTF, 2008). Although these tests are effective not only in
reducing CRC incidence rate but also in decreasing CRC mortality rate, only 64.5% of eligible
adults aged 50 between 75 old with average risk participated to CRC screening in the United
States in 2008 (CDC, 2013). Factors that contribute to the low CRC screening rate may vary, but
lack of access to health care services among low socioeconomic groups and minority groups may
be one of major contributors. The purposes of this paper are to explore, provide a framework for
implementing, and conduct a cost benefit analysis of the Influenza Shot and Home Testing Kit
for FOBT program (FluFOBT) that targets low-income populations aged 50 to 80 years.
The Institute of Medicine (IOM, 2003) pointed out the existence of disparities in
health care in a comprehensive review of racial and ethnic disparities in health care in 2003.

Additionally, according to a report by the Kaiser Family Foundation Commission on Medicaid
and the uninsured, racial/ethnic minorities are more likely to lack insurance coverage and to live
in low income households compared with non-Latino Whites ( Garfield, Damico, Stephens, &
Rouhani, 2014). The report also indicated that uninsured adults are less likely to receive
preventive care and services that focus on disease prevention and heath maintenance, including
screening for cancer (Garfield et al., 2014). Ward et al. (2004) also highlighted inequalities in
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cancer incidence, mortality, and survival related to poverty. The incidence rates and advanced
stage of diagnosis of CRC are likely higher among minority populations (Grubbs et al., 2013).
Wong, Gildengorin, Nguyen, and Mock (2007) found that the CRC screening rate was low
among Asian-American groups in California compared with non-Latino Whites. Morbidity and
Mortality Weekly Report (U. S. Department of Health and Human Services, 2011) provided
similar findings on CRC incidence and screening in United States in 2008 and 2010;
considerably lower overall CRC screening rate among Asian/Pacific Islander (CDC, 2013).
Regrettably, Berry et al. (2009) showed that African Americans are disproportionally burdened
with CRC, having the highest CRC incidence rate across all races (CDC, 2013; Lawsin,
DuHamel, Weiss, Rakowski, & Jandorf, 2006).
CRC can be costly for both patients and the healthcare system (Howard, Tangka, Seeff,
Richardson, & Ekwueme, 2009). The cost for caring for cancer in 2010 was projected to be
$124.57 billion nationally (Mariotto, Yabroff, Shao, Feuer, & Brown, 2011). Of that, the cost of
caring for patients with CRC was predicted to be $14.14 billion, the second highest cost in 2010
after caring for breast cancer, and the highest cost of initial care (Mariotto et al., 2011). In a
study estimating the cost attributable to colon cancer by cancer stage, comorbidity, and patient
characteristics, it was found that the mean total cost for colon cancer one year after diagnosis
was $29,196 (Luo, Bradley, Dahman, & Gardiner, 2009). Luo et al. (2009) also demonstrated
that the cost for caring for a patient with CRC in situ, or local stage, was $27,551, while the cost
for a patient with distant stage CRC was $29,933. They found that patient comorbidities
influenced costs. For example, one, two, three, or more of comorbidities increased the cost by
$2,762, $3,095, and $7, 717, respectively (Luo et al., 2009).
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CRC screening has been shown to be cost-effective compared to no screening. In a
systematic review for USPSTF, Telford, Levy, Sambrook, Zou, and Enns (2010) showed that the
cost savings for CRC screening when compared with no screening was less than $50,000 per
life-year-gain (LYG). A similar review of 32 published articles regarding to the costeffectiveness of CRC screening by Lansdorp-Vogelaar, Knudson, and Brenner (2011) found that
cost-savings per LYG were more than $56,000 and $3,400 to $16,000 respectively by employing
annual gFOBT and biennial gFOBT when compared with no screening in the U.S. On the other
hand, the cost-savings per LYG for colonoscopy was up to $34,000 (Lansdorp-Vogelaar et al.,
2009). Additionally, lost productivity per CRC death was estimated at $288,468 in 2006 (CDC,
2011). Evidence clearly suggests that the healthcare system needs new innovations to improve
CRC screening rates.
Frazier, Colditz, Fuchs, and Kuntz (2000) demonstrated that CRC screening compared
with no screening substantially decreases CRC mortality by 80 percent and prevents CRC
incidence by 60 percent at costs similar to other cancer screening tests. Telford et al. (2010)
found that a reduction in CRC incidence and mortality by 44 percent and 81 respectively by
performing FOBT annually. Other researchers also showed similar results. Hewitson, Glasziou,
Watson, Towler, and Irwig (2008) conducted a Cochrane systemic review of four RCTs and
concluded that annual and biennial screening with FOBT reduced CRC mortality by 16 percent.
Lindholm, Brevinge, and Haglind (2008) found that employing FOBT reduced CRC mortality by
16 percent. Clearly, utilizing FOBT may be an effective way to increase CRC screening rates,
and one innovation, the “FluFOBT program,” appears to be a promising strategy in promoting
CRC screening.
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The FluFOBT program offers an influenza shot and a home FOBT Kit if eligible patients
are due for CRC screening when they come in for a primary care visit during the flu season.
This innovative program could be implemented in public health centers and primary care clinic
settings to increase CRC screening rates among low-income, uninsured or underinsured eligible
adults. The purposes of this paper are to explore, provide a framework for implementing, and
conduct a cost benefit analysis of the influenza Shot and Home Testing Kit for FOBT program
(FluFOBT) that targets low-income population age 50 to 75 years.
Description of the Innovation
It is critical to find a solution that will promote CRC screening for low-income,
uninsured/underinsured population. A hopeful solution for accomplishing this goal may be
utilizing a program known as the FluFOBT. The FluFOBT was developed by Dr. Michael Potter,
a physician at University of California San Francisco Department of Family and Community
Medicine, and his research team. Development, implementation, and evaluation of the program
were funded by CDC and American Cancer Society (ACS), the HMO Cancer Research Network,
and the Alexander and Margaret Stewart Trust. In 2013, the Prevent Cancer Foundation awarded
the program a “Cancer Prevention Laurel for Innovative Programs,” given to the innovators and
leaders who made a significant contribution to cancer prevention.
The strength of evidence for this program was graded as moderate, meaning that “the
available evidence is sufficient to determine the effects of the preventive service on health
outcomes” based on the grading definition by USPSTF Grading Definition (2013).
A pilot test of the program was launched during the flu season at the Chinatown Public
Health Center (CPHC) in San Francisco in 2008. Eight primary care clinicians at the CPHC in
San Francisco provide care mostly monolingual Cantonese-speaking Chinese immigrants who
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live in the Chinatown neighborhood. The clinic handles roughly 14,000 visits each year. The
target population for this program was low-income patients aged 50 to 80 years who had not
received a recommendation for CRC screening in the previous year. A nurse fluent in Cantonese
screened eligibility for CRC screening by reviewing electronic health records (EHR) prior to a
patient seeing a healthcare provider. The nurse asked patients if they were interested in getting a
flu shot and administered the shot to those who desired it. During this time, the nurse evaluated
eligible patients by asking if they were interested in learning about CRC screening.
The nurse provided a brief introduction to CRC screening and showed a 4-minute video in
Cantonese that explained CRC screening in detail to those who were interested. The nurse then
offered answers to any questions the patients may have had and provided a home FOBT kit and a
pre-paid envelope with written return address to those who desired to be screened. The nurse
entered the patients’ responses about receiving an influenza shot and the FOBT kit to the EHR.
Patients who were given a home FOBT kit were provided with instructions in Cantonese on its
use and given a pre-paid return envelope. The patients returned the completed kit using the prepaid envelope to the program’s participating laboratory. Patients received negative results by a
mail, but those returning positive results were contacted to schedule a follow-up diagnostic
evaluation.
Cost Benefits Analysis
Currently, no formal cost-benefit analyses of the program is available in the literature
except for the studies performed by the researchers involved in Dr. Potter’s program. The costeffective analysis on CRC screening using FOBT by Lejeune, DanCourt, Arveux, BonithonKopp, and Faivre (2010) demonstrated that the price of FOBT kits strongly influenced the costeffectiveness results. A large study in the Netherlands by Rossume et al. (2010) reported that a
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single FIT screening compared with no screening resulted 13,400 life-years gained and €320
million (≈ $361.6 million) saved over a period of 10 years. In addition, CRC screening saves
$10,000 to $25,000 per year of life, according to Pignone, Saha, Hoerger, and Mandelblatt
(2002). A study in the Lecco province of Italy by Parente et al. (2014), showed mean total cost
for the first year of diagnosis were €16,435 ($18,571 based on the current money value) vs.
€20,862 ($23,574) vs. €29,845($33,725) vs. €37,288($42,135) for stage I vs. II vs. III vs. IV,
respectively.
Cost
The cost of this innovation will be estimated based on the information provided in the
evaluation of the program at the CPHC in San Francisco by Dr. Potter and his colleagues. The
program does not require new staff members or additional building space because it utilizes the
current nursing staff at the existing clinic settings. However, the program does involve costs for
training the nursing staff (a 1-hour session), purchasing program materials, and supplementary
FOBT kits. Educational materials, including a multilingual educational video for patients, can be
downloaded from htt://flufit.org site at no cost. Screening costs per person vary by test; however,
the estimated cost for FOBT kits range from $5 (Lansdorp-Vogelaar et al., 2011), $10 (Singhal et
al., 2014) to $30 (Taber, Aspinwall, Heichman, & Kinney, 2014). Singhal et al. (2014) used a
median estimated standardized worldwide cost for FOBT and colonoscopy at $10 and $1,000
respectively (rounded to closest whole numbers). The price for FOBT in the U.S. is higher than
those in Europe based on the findings by Lejeune et al. (2010). The prices for FIT were ranged
from $17.25 to $95 (Lansdorp-Vogelaar, et al., 2009; Mayo Clinic Medical Laboratories, 2013).
In order to estimate the cost for training nursing staff, hourly wages of registered nurses
(RN), licensed practical nurses (LPN), and nursing assistants were obtained from Bureau of
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Labor Statistics at the U.S. Department of Labor (2014). The average hourly wage for RNs,
LPNs, and nursing assistants in Kentucky in 2013 were estimated as $27.65, $18.21, and $11.20
respectively (U.S. Department of Labor, 2014). According to Mayo Clinic Medical Laboratories
(2013), the cost for running tests of guaiac based FOBT and FIT were $24 and $95 and were
reimbursed by Medicare at the flat rate of $22. With two licensed practical nurses (LPNs) and
six nursing assistants (NAs), the cost for training nursing the staff would be $103.62 ($36.42 for
two LPNs, and $67.20 for six nursing assistants). The cost for program leaders responsible for
organizing and implementing the program will be covered as part of their regular job salaries.
As a result, there would be no extra cost spending.
Six providers (4 physicians & 2 advanced practice registered nurse [APRN]) see an
average of 500 patients per month. Reflecting to current American population demographics,
about 165 patients out of every 500 would be older than 50 years. Of those, approximately 60
patients, based on the current CRC screening rate of 64.5%, may be eligible for CRC screening.
The months were counted based on 4 months of the flu months (October through January).
Nearly 240 FOBT kits (60 patients for 4months) will be needed. Demand for FOBT/FIT kit may
vary. Based on the demand for 240 FOBT/FIT kits, the costs for gFOBT will be $2,400 $7,200/$4,140 - $22,800 (removing two extreme costs of $5 and $59).
The cost for making postcards for advertising the program are $50 for 1 box (400
postcards) at Vistaprint® (about 33% of 1,200 patients per month) and the postcards can be sent
for $0.34 each ($136). The posters can be downloaded and do not cost extra. The cost for
making postcards and sending them out is about $190. The total cost for implementing
FluFOBT program ranged from (to the nearest dollar) $1,873 to $3,873 vs. $9,348 to $17,123
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based on using gFOBT vs. FIT (see Tables 1.2 & 1.2). The large discrepancy between the low
limit and the high limit resulted from the difference in the reported FOBT pricing.
On the other hand, a colonoscopy costs are considerably high compared to the cost of
gFOBT or FIT. The costs for a colonoscopy vary and are largely determined by service fees.
Services necessary for a colonoscopy without a biopsy include facility services, physician
services, and anesthesia services (Healthcare BlueBook, 2015). According to a report by the
Healthcare BlueBook (2015), the fees for facility services, physician services, and anesthesia
services were $692, $421, and $524, respectively, based on performance as outpatient procedure
with average surgery time of 45 minutes. Thus the total costs of necessary services for a
colonoscopy sums up to about $1,637. However, the actual costs charged for a colonoscopy
differs immensely: $533 to $1,570 (Lansdorp-Vogelaar et al., 2009); $1,397 (DeBarros & Steele ,
2013); and $1,000 using the median estimated standardized worldwide cost reported by Singhal
et al. (2014). Thus, based on the estimated average cost for a colonoscopy reported by the
sources above, it may be expected that costs range per person between $1,000- $1,650 (removing
the extreme outlier $533 from this estimation). A possible cause of the variance in the abovequoted costs may be a result of the procedure being performed with or without anesthesia.
Benefits
Pignone et al. (2002) and Lansdorp-Vogelaar et al. (2009) demonstrated savings of
$10,000 to $25,000 per year of life and nearly $26,000 per LYG in the program with annual
FOBT screening. On the other hand, a study by Parente et al. (2014) in Italy showed the cost for
first year diagnosis ranged from €16,435 ($18,571) to €37,288 ($42,135). The FluFOBT
program can screen for 75 to 100 patients at a cost of $3,196.82- $7,996.82 or $21,996.82 to
$40,636.82 (See Tables 1.1 & 1.2). The average total annual costs for caring for patients with
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CRC were estimated at between $12,231 to $18,359, based on the Surveillance Epidemiology
and End Results (SEER) Medicare approach, considered to be the most accurate in identifying
CRC patients (Yabroff et al., 2009). However, the annual medical expenditure costs using
Medical Expenditure Panel Survey (MEPS) were significantly less with $8,091 for males and
$8,412 for females compared with those who were without cancer (CDC, 2014b). In addition,
the annual productivity losses were estimated at $3,719 for males and $4,033 for females due
largely to employment disability of 75% (CDC, 2014b). Patients with CRC also experience
intangible losses that were not included in the cost-benefit analysis and that cannot be expressed
in monetary values, including limited physical activities, interference with physical and mental
tasks by cancer treatments (CDC, 2014b), and quality of life.
Conclusion of Cost-Benefit Analysis
The FluFOBT program has proven its effectiveness in increasing CRC screening rates.
Evaluation of the piolet program launched in 2008 demonstrated a significant increase of CRC
screening rates to 75.3% from 57.3% compared with an increase of 1.7% among eligible patients
who did not participate in the program during the program’s first influenza season (Walsh,
Gildengorin, Green, Jenkins, & Potter, 2012). A cost-benefit analysis shows a cost-savings per
person of $11,810 for men and $12,445 for women (see Table 2), which are similar to the cost
savings of $10,000 to $25,000 per year of life demonstrated by Pignone et al. (2002). The cost
of implementing a FluFOBT program were estimated at between $3,196.82- $7,996.82 when
using gFOBT and $21,996.82- $40, 636.82 when using FIT (Tables 1.1& 1.2). Nearly 1-4
programs can be implemented with a cost savings of $11,810 -$12,445. One FluFOBT program
can be implemented with a cost saving from 2-3 persons by using FIT. When a FluFOBT
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program is capable of providing 75-100 adults with CRC screening at a cost-savings per person
of $11,810 -$12,445, the cost benefits are significant.
Implementation of the Innovation
The FluFOBT program may be implemented in primary care clinics by utilizing “the
Three Steps of Change” by Kurt Lewin who is recognized as “the founder of the modern social
psychology” (Greathouse, 1997). The change model can be implemented in three steps, detailed
below: the unfreeze step, the move (transition) step, and the refreeze step. The first step in
implementing a new program is to gain supports from top-level administrators and directors by
providing contextual information of the innovation, its goal, and a comprehensive plan. Once
approval for implementing the innovation is obtained, the change model can be applied to
implement the project. The unfreeze step involves building with in a whole group a mood
necessity for change. Understanding group dynamics in regards to driving and restraining forces
may provide valuable information in terms of recognizing individual goals, needs, and fears (Šuc,
Prokosch, & Ganslandt, 2009). Identifying the principle promoters and opponents of the project
can be accomplished during workshops and by performing informal interviews. Designating a
program leader who can make plans for the program is essential. During this phase, feedback,
ideas, and suggestions should be collected and evaluated to minimize conflicts during program
implementation.
The move (transition) step involves processing all changes required to be made. The first
step should involve promoting the program’s launch with patients by creating posters and
sending out postcards. In regards to the FluFOBT program, standard steps include: identifying
eligible patients aged 50 to 75 years for CRC screening who visit the clinic during flu season;
asking if they are interested in getting a flu shot and providing a flu shot if interested; asking if
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they are interested in learning more about the FOBT; providing a brief introduction to CRC and
FOBT; ask if they are interested in taking a home FOBT kit; providing a home kit along with a
pre-paid return envelope and one-page instruction sheet and answering, if asked, any questions
about the test; and documenting the procedure in the patients’ charts. Individuals need to learn
new behaviors related to the implementation of the project through training, education, and
communication. In order to ensure the program runs efficiently, nursing staffs need to attend a
1-hour group session, which includes the standard procedures of the program, 1-2 weeks prior to
program launch. To try and assess the program’s impact on day-to-day operations, a small scale
test should be conducted 1-2 days per week before the program is fully operational. The
program’s participating laboratory also needs to ensure it can manage the increased volume of
the FOBT test. Additionally, in order to maintain the effectiveness of the program it is crucial
that gastrointestinal specialists be available to perform colonoscopies in an appropriate time
frame for those who have positive results with the FOBT test. This can be the most stressful
period for individuals who have to learn or adjust to the changes.
The last step involves building reinforcements for sustaining the program after it has been
implemented, in particular, monitoring the ongoing process and outcomes. For example,
program leaders might conduct feedback meetings after auditing patients’ charts. This ongoing
process may lead to recognition that refinements or adjustments to the project have become
necessary, particularly if compliance with the change is less than expected. Program leaders and
top management must provide supports to frontline members who are responsible for running the
program during this time in order to prevent them from relapsing back to old patterns of practice.
Also, if the participation rate is lower than established goals within a specified time frame, it is
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necessary to take extra measures to encourage the remaining patients to return completed tests by
contacting them directly through e-mail, text message, or telephone call.
The effect of the program on its recipients can be determined by performing an
evaluation (Issel, 2009). However, it can become a distraction from the essence of the program
if too many outcomes are considered in an evaluation by producing higher evaluation costs and
producing a vast volume of data to analyze (Issel, 2009). Focusing on the key outcome will
reduce such distractions (Issel, 2009). The program outcome should monitor the completion
rate of CRC screening among FluFOBT program participants versus those who did not
participate in the program while visiting the clinic during flu season.
Conclusion
Because of the significant gaps in CRC screening rates among Americans (CDC, 2013;
Wong et al., 2007), it is important to make efforts not only to improve CRC screening rates
among eligible adults of a low socioeconomic status and racial/ethnic minorities, but also to be
cost effective in achieving that goal. Despite the effectiveness of screening tests in reducing the
incidence and mortality of CRC, the current CRC screening rate is unsatisfactory. Implementing
the FluFOBT program appears to be effective not only in improving CRC screening rates but
also in cost saving. Implementing the FluFOBT program appears to be a promising way to reach
both those of low socioeconomic status and racial/ethnic minorities. The FluFOBT program
should be encouraged to be used as an optional program that is effective for many eligible adults
with inexpensive costs.
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Table 1.1 The Cost for Implementing FluFOBT Program
COST

NUMBER

TOTAL

gFOBT kit

$10 - $30

240

$2,400-$7,200

Cost for testing

$24 - $22

240

$480

(reimburse by
Medicare)
=$2
Nursing assistant

$11.20

6

$67.20

LPN

$18.21

2

$36.42

Stamps for return

$0.34

240

$81.60

Postcards

$50

1box

$50

Stamps for

$0.34

240

$81.60

Kit

postcards
Total

$3,196.82- $7,996.82

Table 1.2 The Cost for Implementing FluFOBT Program

COST

NUMBER

TOTAL

FIT kit

$17. 25- $95

240

$4,140- $22,800

Cost for testing

$95-$22 (reimburse

240

$17,520

by Medicare)=$73
Nursing assistant

$11.20

6

$67.20

LPN

$18.21

2

$36.42

Stamps for return

$0.34

240

$81.60

Postcards

$50

1box

$50

Stamps for

$0.34

240

$81.60

Kit

postcards
Total

$21,976.82-$40.636.82
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Table 2 Cost per Colorectal Cancer
Annual Medical

Male

Female

$8,091

$8,412

$3,719

$4,033

$11,810

$12,445

expenditure
Annual Productivity
Loss
Total
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Abstract
Purpose: The purpose of this project was to examine the relationship between advanced practice
registered nurse (APRN) knowledge about the U.S. Preventive Service Task Force (USPSTF)
colorectal cancer (CRC) screening recommendations guideline and self-reported referral rates for
CRC screening among APRNs.
Methods: A descriptive internet survey was conducted to examine APRN knowledge about the
USPSTF CRC screening recommendation guidelines and their self-reported referral rates for
CRC screening by administering the Modified Test Your Knowledge Survey to APRNs.
Results: APRNs self-reported CRC screening referral rates were not associated with their
knowledge levels. In addition, APRNs lacked knowledge not only in categorizing risk level of
individuals, but also in utilizing the FOBT appropriately.
Conclusions: Although there was no relationship between APRNs knowledge level of USPSTF
CRC screening recommendations guidelines and their self-reported CRC screening referral rates,
adequate knowledge of the current guidelines are essential for APRNs in order to provide
evidence-based safe care. Thus, efforts must be made to improve APRNs risk assessment skills
and proper utilizations of FOBT.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in the U.S., with a lifetime risk
of 5.7 % for men and 5.1 % for women in the U.S. (U.S. Preventive Service Task Force
[USPSTF], 2008). Despite the fact individuals can choose among a number of preferred CRC
screening tests recommended by the latest USPSTF, unless significant improvement is made in
screening rates, CRC prevalence may continue to grow among the aging American population
(USPSTF, 2008). Roughly 93% of diagnoses were made among adults older than 50 years of
age (Weinberg, 2008). Although CRC incidence rates have been declining annually by 3.4% and
mortality rates by 3.0% in recent years (Centers for Disease Control and Prevention [CDC],
2013a), participation in CRC screening reached only 64.5% of eligible adults in 2008 (CDC,
2013a). The Healthy People 2020 cancer objective aims to increase the CRC screening rate to
70.5% (U.S. Department of Health and Human Services [HHS], 2015).
CRC is one of the most highly preventable cancers if individuals participate in screening.
The risk for incidence and death of CRC caused by late detection and late intervention can be
significantly reduced by adhering to the most recent USPSTF (2008) recommendation guidelines
for CRC screening, published in 2008. The USPSTF recommendations are (a) to routinely
screen adults aged 50 to 75; (b) to not routinely screen adults aged 76 to 85; and (c) to not screen
adults older than 85 (USPSTF, 2008). Understanding barriers to CRC screening is critical in
encouraging eligible adults to participate in screening.
Barriers to CRC screening result from multiple factors. Jones, Devers, Kuzel, and Woolf
(2010) identified bowel preparation and fear as the most widespread barrier to screening in their
study. Green et al., (2008) also described the fear of pain related to the colonoscopy procedure
and a diagnosis of CRC as perceived barriers by patients. Jones et al., (2010) also identified
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barriers including financial and language difficulties. Lack of a provider’s recommendation for
CRC screening also was a common theme in discussing barriers to CRC screening. Lasser,
Ayanian, Fletcher, and Good (2008) identified “no doctor’s recommendation” as one of barriers
in their study, and Kelly et al., (2007) and Jones et al., (2010) found that lack of physician
recommendation was a barrier to CRC screening. Not surprisingly, other researchers identified a
provider recommendation as the most powerful influence on patient decision to undergo CRC
screening (Davis et al., 2013; Haverkamp, Perdue, Espey, & Cobb, 2011; Klaunde, Vernon,
Nadel, Breen, Seeff, & Brown, 2005; Sarfaty, 2008).
Primary care providers (PCPs) usually initiate CRC screening by making a referral for
one of the recommended screening tests (Katz et al., 2012; Ornstein, Nemeth, Jenkins, & Nietert,
2010). Thus, insufficient knowledge of CRC and USPSTF CRC screening guidelines may result
in eligible adults being overlooked for CRC screening (USPSTF, 2008). In a survey of internal
medicine resident knowledge (n=81), Barrison, Smith, Oviedo, Heeren, and Schroy (2003)
concluded that the residents lacked necessary risk assessment skills and knowledge about CRC
screening recommendations. Gennarelli et al. (2005) arrived at similar results regarding low
physician knowledge of CRC screening guidelines for average-risk patients. Additionally,
O’Farrell, Green, Reid, Bowen, and Baldwin (2012) found that CRC screening rates were higher
among patients who received a physician’s recommendation compared with those patients who
did not. Based on these findings, insufficient knowledge regarding screening guidelines among
PCPs may negatively affect their ability to offer appropriate screening recommendations to
eligible adults.
Advanced practice registered nurses (APRNs) make up nearly 25% of primary care
providers in the U. S. (Institution of Medicine [IOM], 2011). Growth in the number of APRNs is
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gradually rising while medical students and residents entering primary care are declining (IOM,
2011). Understanding APRNs knowledge of CRC screening recommendation guidelines is
essential. It is also important to recognize the relationship between their knowledge level and
their referral rates in order to improve CRC screening rates. Nevertheless, there are no published
studies on APRN knowledge about the USPSTF CRC screening recommendation guidelines. In
an effort to determine how CRC screening rates could be increased, two questions arose. What
do APRNs know about the USPSTF CRC recommendation guidelines? Is there a relationship
between APRN knowledge regarding the USPSTF CRC recommendations and their self-reported
referral rate for CRC screening?
Purpose
The purpose of this project was to examine the relationship between APRN knowledge
about the USPSTF CRC screening recommendation guidelines and self-reported referral rates for
CRC screening among APRNs.
The aims of this project were to determine; (1) demographic characteristics of APRNs;
(2) APRNs knowledge levels about the USPSTF CRC screening recommendation guidelines; (3)
the referral rate of APRNs by collecting participant self-reported screening rates; (4) whether
educational background is associated with the self-reported referral rates; and (5) the relationship
between an APRNs knowledge level about the USPSTF CRC screening recommendation
guidelines and the self-reported referral rates for CRC screening.
Methods
Study Design and Sample
A descriptive internet survey was conducted to examine APRN knowledge about the
2008 USPSTF CRC screening recommendations and self-reported referral rates for CRC
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screening. The Test Your Knowledge Survey (Sarfaty, 2008, Appendix A) was modified and
administered to APRNs through the Kentucky Coalition of Nurse Practitioners and Nurse
Midwives listserv (KCNPNM) from January 5 through March 5, 2015.
Currently, 5,321APRNs are registered in Kentucky, with each role broken down as
follows; nurse anesthetist (1,215), nurse specialist (178), nurse midwives (100), and nurse
practitioner (3,828) (Kentucky Board of Nursing, 2014). Inclusion criteria for this study were (a)
APRNs over 18 years old who are subscribers to the KCNPNM listserv; (b) are currently
practicing in Kentucky 12 hours or more each week in general practice, family practice, internal
medicine, gastroenterology practice, and obstetrics/ gynecology. Exclusion criteria for this study
were APRN nursing students who were subscribers to the KCNPNM listserv.
Subject Recruitment
The initial contact with potential eligible participants was made by sending an e-mail via
the KCNPNM listserv to all 1,526 subscribing member of KCNPNM on January 5th, 2015 after
obtaining permission from the University of Kentucky Medical Institutional Review Board and
the Executive Director of KCNPNM (Appendix B). The e-mail included an invitation to
participate in the study, information about the study, and a link to access the survey. Follow up
e-mails were sent as a reminder to complete the survey to all 1,526 subscribing members of
KCNPNM four more times during January and February after the initial e-mail.
Informed Consent Process
The e-mail explained the purpose of this project, anticipated benefits and risks, limitation
of confidentiality due to the nature of an online survey, contact information, and statements
describing type of participation, and no penalties or loss of benefits for not participating or
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withdrawing from the study if they should desire. Participation was voluntary. Completion of
the survey constituted consent.
Research Procedures
The Test Your Knowledge Survey was developed as a part of a toolbox to guide primary
care providers in promotion of CRC screening (Sarfaty, 2008). The Test Your Knowledge
survey was modified to include items related to demographics and referral rates. The survey
consists of twenty questions. The first ten questions are related to improving screening rates in
practice, and the remaining ten questions focused on the current screening recommendation
guidelines. The modified survey is organized into the following four sections; (a) practice and
other demographic characteristics; (b) attitude toward improving CRC screening rates in
practice; (c) knowledge of CRC screening modalities and recommendation guidelines; and (d)
self-reported CRC screening recommendation rate.
Items inquiring about APRN attitudes toward improving CRC screening rates focused on
evidence-based essential elements that are effective in improving CRC screening rates (Sarfaty,
2008). These elements include provider recommendation, an office policy about assessing
individual risk and insurance coverage, identifying local medical resources and considering
patient preference, an office reminder system, and an effective communication system between a
provider and patients.
Items assessing APRN knowledge about CRC recommendation guidelines focused on
categorizing the risk level of individual patients and applying appropriate CRC screening tests.
The item evaluating APRNs’ self-reported referral rate was measured by using a four-point
Likert scale that contains “very often”(90-100%), “often” (75-90%), “average”(50-75%), “not
often”(less than 50%) after reviewing the USPSTF CRC screening recommendation guidelines
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(Appendix C). Each question was coded 1 for correct response and 0 for incorrect response and
a total survey score was calculated for each participant. Question 21 was added to evaluate selfreported APRN referral rates. Questions 22 -31 were added to examine the participant
demographics. Thus, the participants were asked about their age, gender, level of nursing
education, years of practice as an APRN, the type of APRN license held, type of the clinical
setting and county in which they practiced, working hours each week, and average number of
patients they see each week. REDCap was used to collect and store data. REDCap is a secure
web-based application that supports and manages data capture for small/medium-sized research
studies (Harris et al., 2009). Data were securely kept on Biomedical Informatics servers ran by
the Institute for Pharmaceutical Outcomes and Policy (IPOP) physically located in the new
Biological and Pharmaceutical Complex building at the University of Kentucky.
Data Analysis
Statistical analysis was performed using SPSS. Descriptive statistics were utilized to
describe the sample. Frequencies were calculated for each variable. A McNemar Chi-square test
(2x2) was used to examine the relationship between APRN knowledge and self-reported referral
rates for CRC. If McNemar Chi-square statistic value is > 3.84 and p value is < 0.05, the null
hypothesis will be rejected. A p value <0.05 is considered statistically significant.
Results
Demographic characteristics
Ninety-seven participants were recruited from January 5 to March 5, 2015. Of those, 34
participants were excluded based on the incompletion of survey, inability to provide selfreported referral rates for CRC screening due to their practice backgrounds (a thoracic unit, an
acute care unit, a retail clinic, & cardiology), practice out of Kentucky, working less than 12
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hours per week, retired, or student. Of the remaining 63 participants, a majority (n=59; 93.7%)
were female, which reflects the national average (≈92%) of female nurses in nursing fields (U.S.
Census Bureau, 2013). Master’s prepared APRNs (nearly 75%) dominated the sample while
20.7% were doctorally prepared APRNs. APRNs had been in practice for an average of 11.6
years and an average of 49.8 years old. APRNs from 30 counties participated with the highest
participation rate coming from Jefferson County. Demographic characteristics are provided in
Table 3.
Regarding attitudes toward improving CRC screening rates in practice, only 44.4% (n=28)
of APRNs recognized “a recommendation” as the most effective tool for encouraging patients to
be screened. One hundred percent (n=63) of APRNs acknowledged that “postcard reminders”,
“reminder letters”, “prescription reminders”, and “telephone calls” would be effective in
improving CRC screening rate, but only 53% of these responded that all four have been
demonstrated to be effective. Only 57.1% (n=36) responded to the effectiveness of all four of
the chart prompts including “problem lists”, “screening schedules”, “electronic medical record
reminders”, and “chart stickers”. On the other hand, nearly 96.8% (n=61) of APRNs identified
“provider feedback” as an effective way to improve CRC screening. Over 90% (n=57) of
APRNs also acknowledged involving office staffs in the screening process can facilitate
improving CRC screening. Table 4 illustrates the results on APRNs attitude toward improving
CRC screening rates in practice.
Overall test scores for knowledge level of USPSTF CRC screening recommendation
guidelines were 77.9%. The first six questions which were focused on assessing attitudes toward
improving CRC screening rates in practice were not included in the overall test scores because
they were not related in the evaluation of APRNs knowledge of CRC screening recommendation
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guidelines by USPSTF (see Figure 1). Answers were coded either 1 point for a correct response
or 0 point for incorrect response. The maximum score was 14 points. A total survey score was
calculated for each participant. The distribution of scores is exhibited in Figure 1. Three APRNs
answered all questions correctly, while one APRN scored 6, the lowest score. The mean score ±
standard deviation was 10.9 ± 2.06 and median of 11.
The majority of APRNs (n=40, 63.5%) answered “false” (correct answer) when asked if
the digital rectal examination is an acceptable CRC screening practice. Regarding whether a
clinician should perform a stool blood test in the office to make sure that at least one CRC
screening test was completed, 60.3% (n=38) of APRNs answered “true” (incorrect answer).
Only 52.4% (n=33) of APRNs answered “false” (correct answer) when asked if a stool blood test
should be repeated when it is returned with only one positive window. 71.4% (n=45) of APRNs
answered “true” (incorrect answer) when asked if a positive stool blood test without following
the diet restrictions should be repeated. APRNs knowledge level regarding rectal examination
and stool blood test are displayed in Table 5.1.
Participants also showed a lack of knowledge when asked to categorize the risk level of
patients as average, increased, or high based on the current screening guidelines. For example,
74.6% (n=47) of APRNs answered “high” (incorrect answer) when asked them to categorize the
risk level of a 20 year-old woman whose mother died of colorectal at age 47. More than half of
the APRNs (n=32) also provided incorrect answers to the question that asked to categorize the
risk level of a 30 year old male whose older brother was diagnosed with an adenomatous polyp
at age 59. The average APRNs correct response on categorizing the risk level for four individual
patients was only 40.5%. Table 5.2 illustrates the results on APRNs knowledge of categorizing
the risk levels of individual patients.
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APRNs demonstrated their knowledge regarding CRC screening ages for “average-risk”
patients. Nearly 90% of participants knew individuals with average risk for CRC should screen
at age 50. The majority of participants also knew colonoscopy has the highest sensitivity and
specificity among the recommended modalities and should be used as a follow-up screening test.
Table 5.3 shows the APRNs performance on choosing appropriate modalities for individual
patients.
When APRNs were asked to rate their referral for CRC screening using a four-point
Likert scale that contains “very often”(90-100%), “often” (75-90%), “average”(50-75%), “not
often”(less than 50%), 51% (n=32) of them reported that they made referrals for CRC screening
“very often”, while 33.3% (n=21) reported making referrals “often”. Only 15.9% (n=10) of
APRNs reported that they made referral for CRC screening “average” or “not often”.
Participants who answered “N/A” were excluded from this study. Those responses were
compared with test scores (n=24 who scored ≥ 11 and n=39 who score <11) to determine if there
was a relationship. McNemar’s Chi-square test value was 𝛘2 = 6.21 and p-value = 0.01. Given
the assumption that APRNs who scored higher on the test will have higher referral rates (null
hypothesis), the McNemar statistic value 𝛘2 = 6.21 and p-value = 0.01 rejected this assumption.
As a result, APRNs knowledge level of CRC screening recommendations guideline and their
referral rates were not related. APRNs test scores and their self-reported referral rates for CRC
screening is displayed in Table 6.
There was no difference in test scores and very little difference in self-reported referral
rates by education levels. The majority of APRNs (83%) with MSN degrees reported their
referral rates as “very often” or “often”, 84.6% of APRNs with doctoral degrees reported their
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referral rates as “very often” or “often” while only 63.8% of APRNs with MSN and 62.5% of
APRNs with DNP and PhD scored ≥ 11.
Discussion
Provider’s recommendation for CRC screening has been identified as the most effective
in convincing patients to undergo screening procedures (Davis et al., 2013; Haverkamp et al.,
2011; Klaunde et al., 2005; Sarfaty, 2008). All APRNs in this present study agreed with the
effectiveness of reminder methods such as postcards, letters, and phone calls in increasing CRC
screening rates although not all of them agreed on those reminders as being equally effective.
Other researchers have recognized “no recommendation” as one of the barriers to CRC
screening (Jones et al., 2010; Kelly et al., 2007; Lesser et al., 2008). Less than 50% of APRNs in
this study agreed with the above findings. Green et al. (2013) conducted a study on examining
an automated intervention to increase uptake of CRC screening, including EHR-linked mailings,
telephone assistance, automated assistance plus nurse navigation. Green et al. (2013) found
groups with those interventions, compared with groups with no intervention, were more likely to
be current for CRC screening.
Findings from the present study on APRNs were consistent with studies on physicians
(Barrison et al., 2003; Gennarelli et al., 2005; Nadel et al., 2010). The average APRNs correct
response on categorizing the risk level for four individual patients was only 40.5%. Perhaps
those findings may be explained by inadequate explanation of how to categorize the risk level,
and the complexity of the risk assessment for developing CRC provided by USPSTF CRC
screening recommendation guidelines.
Providers’ knowledge of CRC screening recommendation guidelines is a critical
component in improving CRC screening among eligible adults. A previous study on internal
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medicine residents by Barrison et al. (2003) demonstrated that risk assessment skills on an
individual for developing CRC and knowledge about CRC screening recommendations are
insufficient. Gennarelli et al. (2005) also found physicians lacked knowledge of CRC screening
guidelines for average-risk patients.
Although utilization of FOBT has been decreasing in recent years, FOBT is one of the
recommended modalities for CRC screening by USPSTF. Over 60% of participants considered
the one-time FOBT administration in the office as being an acceptable practice. Additionally,
over 70% of APRNs lacked an understanding that colonoscopy was recommended when a FOBT
showed a positive result regardless of the diet restrictions not being followed. One potential
cause for APRNs poor knowledge level regarding FOBT may be a declining utilization of FOBT
at only 10.4% in recent years (CDC, 2013b).
Many studies have validated that FOBT can reduce CRC incidence and mortality (Bosetti
et al., 2011; Hardcastle et al., 1996; Hewitson et al., 2008; Lindholm et al., 2008; Mandel et al.,
2000; Parente et al., 2014). For example, conducting Cochrane Systemic Review of four RCTs
showed that FOBT reduced CRC mortality by 16% (Hewitson et al., 2008). APRNs
demonstrated insufficient knowledge of utilization of the FOBT. A single digital rectal
examination with FOBT cannot be recommended as the only test due to its poor sensitivity
(4.9%) for detecting CRC (Collins, Lieberman, Durbin, Weiss, & the Veteran Affairs
Cooperative Study # 380 group, 2005). Nadel et al. (2010) described the one-time FOBT given
by PCPs in the office may be worse than no screening because it fails not only in detecting 95%
of cases of advanced neoplasia but also provides a false sense of reassurance.
On the other hand, APRNs were knowledgeable about application of other modalities.
Almost all APRNS knew colonoscopy should be used as the follow-up test. Interestingly, the
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present study found that APRNs knowledge level was not correlated to their self-reported CRC
screening referral rates. Of those (n=24) who scored less than 11, 87.5% indicated that they
made referrals very often or often. In addition, analysis found that no statistically significant
association in self-reported referral rates between APRNs with MSN and APRNS with DNP or
PhD.
Limitations
This study has several limitations. First, an unvalidated instrument was used to measure
APRNs knowledge level. However, validity and reliability for this instrument have not been
tested. Second, the small sample size is a limitation. Sixty-three participants in the present study
represent only 1.2% of total APRNs in Kentucky. Thus, the findings from this study cannot be
generalized to the whole APRN population. Lastly, a self-reported referral rate for CRC
screening method was utilized. This method may potentially lead to bias since true referral rates
could not be determined. A patient’s chart audit by using EHR may help to minimize the bias.
Implications for Practice and Research
Findings from this study indicated APRNs knowledge of utilization of FOBT (one of the
recommended CRC screening tests) and risk assessment skills were lacking. Suggestions to
improve APRNs knowledge in these areas include providing education programs related to
utilization of FOBT and risk assessment skills by employing pre-test and post-test. Offering
continuous educational unit (CEU) credit hours for the educational program may encourage
APRNs to participate in these programs. It may be necessary to produce a simple algorithm of
assessing the risk level for developing CRC of individuals for APRNs to use it as a quick
reference. In addition, it is essential to create a better instrument to measure APRNs level of
CRC screening recommendation guidelines.
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Conclusions
The present study aimed to determine if there was a relationship between APRNs
knowledge level of CRC screening recommendation guidelines and APRNs self-reported CRC
screening referral rates. Findings from this study indicated that APRNs lacked knowledge not
only in categorizing the risk level of individuals, but also in utilizing FOBT appropriately. Thus,
needs for improvement in APRNs knowledge related to risk assessment skills and utilization of
FOBT were identified. APRNs should keep in mind that FOBTs, especially the high-sensitivity
FOBT and FIT, have made significant improvements in their sensitivity. Because of improved
sensitivity of FOBT or FIT, these tests can be a reasonable alternative that can reach to a broadrange of eligible adults. Although APRNs self-reported CRC screening referral rates were not
associated with their knowledge level, sufficient knowledge of the current guidelines are
essential for APRNs in order to provide evidence-based safe care. Efforts must be made to
improve APRNs risk assessment skills and proper utilizations of the FOBT.
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Tables and Figure
Table 3 Demographic Characteristics of APRN
Frequency
Gender

Male
Female
Non-specified

Education

APRN Designation

County

4.8%
93.7%

1

1.5%

47

74.6%

DNP

10

15.9%

PhD

3

4.8%

3

4.8%

1-5 years

22

34.9%

6-10 years

12

19%

11-15 years

6

9.5%

16-20 years

12

19%

21-25 years

0

0%

30 and over years

5

7.9%

Nurse Practitioners

54

85.7%

Nurse Midwives

5

7.9%

Clinical Nurse Specialist

3

4.8%

Nurse Anesthetist
Population Focused

3
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MSN

Others/missing
Years in Practice

Percent

0

0%

Family Practice

36

57.1%

Adult (Adult-Gero)

13

20.6%

Women’s Health

11

17.5%

Acute Care

2

3.2%

Psychiatric Care

1

1.6%

Jefferson

14

22.2%

Fayette

9

14.3%

Hardin

3

4.8%

Breckinridge

2

3.2%

Caldwell

2

3.2%

Daviess

2

3.2%

Franklin

2

3.2%

Pulaski

2

3.2%

22 more counties with an APRN

1

35.2%

62

Table 4 APRNs Attitudes toward Improving Screening Rates in Practice
Frequency
Q 1. The most effective

A recommendation

tool at an APRN’s

(correct answer)

disposal fir encouraging
patients to be screened
is

None of the above

Percent
28

44.4%

An educational pamphlet

7

11.1%

An educational video

1

1.6%

26

41.3%

All of the above

1

1.6%

Q 2. Which of the

Postcard reminders

6

9.5%

following have been

Reminder letters

9

14.3%

demonstrated to be

Prescription reminders

3

4.6%

effective in raising

Telephone calls

9

14.3%

cancer screening rates

All of the above (correct

36

57.1%

answer)
Q 3. Effective chart

Problem lists

0

0%

prompts include

Screening schedules

12

19%

Electronic medical record

14

22.2%

1

1.6%

36

57.1%

reminders
Chart stickers
All of the above (correct
answer)
Q 4. A theory-based

True (correct answer)

48

76.2%

communication

False

13

27.1%

Q 5. Provider feedback

True (correct answer)

61

96.8%

is an effective way to

False

2

3.2%

57

90.5%

4

6.4%

strategy is more
effective than generic
education

improve office
screening rates
Q 6. Reassignment of

True (correct answer)

office staff to involve

False

them in the screening
process can facilitate
improved screening
rates
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Table 5.1 APRN Knowledge Level about the USPSTF CRC Screening Recommendation Guidelines
Frequency

Percent

Q 7. The digital rectal

True

23

36.5%

exam in an accepted

False (correct answer)

40

63.5%

Q 8. Clinician should do a

True

38

60.3%

stool blood test in the

False (correct answer)

25

39.7%

Q 9. If a stool blood test

True

30

47.6%

kit is returned and only

False (correct answer)

33

52.4%

Q 10. A positive stool

True

45

71.4%

blood test should be

False (correct answer)

18

28.6%

colorectal cancer screening
practice.

office to make sure that at
least one CRC screening
test is completed.

one window is positive, the
test should be repeated.

repeated if the diet
restriction were not
followed,

Table 5.2 APRN Knowledge Level about the USPSTF CRC Screening Recommendation Guidelines
Frequency

Percent

Q 11. A 45 year old woman

Average (correct answer)

24

38.1%

whose father was

Increased

33

52.4%

diagnosed with colorectal

High

5

7.9%

cancer at age 70?

Missing =1
Q 12. A 30 year old male

Average

14

22.2%

whose older brother was

Increased (correct answer)

30

47.6%

diagnosed with an

High

18

28.6%

Q 13. A 50 year old female

Average (correct answer)

33

52.4%

whose uncle was

Increased

24

38.1%

diagnosed with

High

6

9.5%

adenomatous polyp at age
59.

Missing =1

adenomatous polyps at
age 55.
Q 14. A 20 year old woman

Average

0

0%

whose mother died of

Increased (correct answer)

15

23.8%

colorectal at age 47

High

47

74.6%

Missing =1
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Table 5.3 APRN Knowledge Level about the USPSTF CRC Screening Recommendation Guidelines
Frequency

Percent

Q 15. At what age should

Puberty

0

0%

“average-risk” patient

Age 25

2

3.2%

begin colorectal cancer

Age 40

5

7.9%

screening?

Age 50 (correct answer)

56

88.9%

0

0%

Age 60

Missing=0
Q 16. At what age should a

Puberty

1

1.6%

patient with family history

Age 25

8

12.7%

of colorectal cancer or

Age 40 (correct answer)

46

73.0%

adenomatous polyps

Age 50

8

12.7%

affecting one first-degree

Age 60

0

0%

relative diagnosed at age

Missing=0

55 begin screening?
Q 17. What screening

Stool blood test

1

1.6%

modality offers the

Stool blood

5

7.9%

greatest sensitivity and

test/Flexible Sig.

specificity and should be

Flexible sigmoidoscopy

recommended to those at

Colonoscopy (correct

increased risk?

answer)
Double–contrast barium

4

6.3%

53

84.1%

0

0%

0

0%

enema

Missing=0
Q 18. What screening

Stool blood test

51

81%

modality might be best to

(correct ans.)

5

7.9%

recommend to a patient

Stool blood

0

0%

who is distrustful of

test/Flexible Sig.

3

4.8%

physicians or very

Flexible sigmoidoscopy

4

6.3%

uncomfortable with

Colonoscopy

invasive procedures?

Double–contrast barium

0

0%

enema

Missing=0

Q 20. Which of the

Stool blood test

1

1.6%

following screening test(s)

Flexible Sigmoidoscopy

3

4.8%

are recommended by one

Stool DNA testing

or more authoritative

Colonoscopy (correct

groups for patient at risk

4

6.3%

52

82.5%

answer)

1

1.6%

of hereditary non-

Double–contrast barium

0

0%

polyposis colon cancer or

enema

0

0%

familial adenomatous

All of the above

polyposis?

Missing=2
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Table 6 Test Scores and Self-Reported Referral Rates for CRC Screening
Referral Rate

Referral Rate

≥ 75%

< 75%

Total

Test Score ≥ 11

32 (82.1%)

7 (17.9%)

39

Test Score <11

21 (87.5%)

3 (12.5%)

24

Total

53

10
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Figure 1 Distribution of Test Scores

score 14

8% 4%
9%

score 13
16%

score 12
score 11

10%
15%

score10
score 9

11%

score 8
13%

14%

score 7
score 6
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Colorectal cancer (CRC) is the second leading cause of cancer deaths in both men and
women in the United States. The Centers for Disease Control reports that 51,783 people died
from CRC in 2011. CRC can be prevented by participating in recommended screening tests
including fecal occult blood test (FOBT) such as high-sensitivity FOBT or fecal
immunochemical test (FIT) annually. However, only 64.5% of eligible adults were screened for
CRC in 2008. Factors contributing to the low CRC screening may vary, but several barriers
including invasive screening methods (fear, bowel preparation, and unwillingness to undergo),
lack of access to health care services, and lack of provider’s recommendation due to insufficient
knowledge related to the current CRC screening recommendation guidelines have been identified.
It is critical to overcome these barriers for improving CRC screening rates among eligible adults
in the United States.
Efforts must be made to improve CRC screening rates among eligible adults. Several
strategies for overcoming these barriers were identified from conducting the DNP practice
inquiry project. To increase utilization of high-sensitivity FOBT or FIT annually for those who
are reluctant to undergo the invasive screening tests or for low-income adults who have lack of
access to health care services may help to overcome barriers related to the invasive screening
tests. Although the sensitivity of FOBT is not as high as of colonoscopy, employing FOBT has
demonstrated its effectiveness not only in reducing CRC mortality and incidence rates but also in
increasing participation rates to CRC screening. The current low utilization of FOBT at 10.4%
in recent years should be increasing.
Even though the present study found that there was no relationship between APRNs
knowledge level about the USPSTF CRC screening recommendation guidelines and their selfreported CRC screening rates, providers’ sufficient knowledge of the current guideline is critical
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in providing evidence-based safe care. To provide educational programs to APRNs about the
current CRC screening recommendation guidelines would improve their knowledge. Developing
a simple algorithm of assessing risk level of individual patients by USPSTF may be necessary
for providers to use as a quick guide in determining risk level for an individual. As a result, this
may lead to more referrals for CRC screening. On the other hands, a better instrument that can
measure APRNs knowledge level appropriately should be developed in future research.
Implementing the FluFOBT program may be a strategy in improving CRC screening
rates. Evaluation of the pilot program at the Chinatown Public Health Center (CPHC) in San
Francisco launched in 2008 demonstrated a significant increase of CRC screening rates to 75.3%
from 57.3% among those who were participated in the program. Overcoming the above barriers
appears to support efforts for increasing CRC screening rates.
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Appendix A
Improving Screening Rates in Practice
1. The most effective tool at an APRN’s disposal for encouraging patients to be screened is:
a. A recommendation
b. An education pamphlet
c. An educational video
d. None of the above
e. All of the above
2. Which of the following have been demonstrated to be effective in raising cancer screening
rates?
a. Postcard reminders
b. Reminder letters
c. Prescription reminders
d. Telephone calls
e. All of the above
3. Effective chart prompts include:
a. Problem lists
b. Screening schedules
c. Electronic medical record reminders
d. Chart stickers
e. All of the above
Choose whether the statements are true or false. (True/ False)
4. A theory-based communication strategy is more effective than generic education. (T/ F)
5. Provider feedback is an effective way to improve office screening rates. (T/ F)
6. Reassignment of office staff to involve them in the screening process can facilitate improved
screening rates. (T/ F)
7. The digital rectal exam is an accepted colorectal cancer screening practice. (T / F)
8. Clinicians should do a stool blood test in the office to make sure that at least one CRC
screening test is completed. (T / F)
9. If a stool blood test kit is returned and only one window is positive, the test should be
repeated. (T / F)
10. A positive stool blood test should be repeated if the diet restrictions were not followed.
(T /F)
The Current Screening Guidelines Categorize the risk level of the following patients as
average, increased, or high.
11. A 45-year-old woman whose father was diagnosed with a colorectal cancer at age 70
Average
Increased
High
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12. A 30-year-old male whose older brother was diagnosed with an adenomatous polyp at age
59.
Average
Increased
High
13. A 50-year-old female whose uncle was diagnosed with an adenomatous polyp at age 55.
Average
Increased
High
14. A 20-year-old woman whose mother died of colorectal at age 47.
Average
Increased
High
15. At what age should “average-risk” patients begin colorectal cancer screening?
____ Puberty ____ Age 25 ____ Age 40 ____ Age 50 ____ Age 60
16. At what age should a patient with a family history of colorectal cancer or adenomatous
polyps affecting one first-degree relative diagnosed at age 55 begin screening?
____ Puberty
Age 25
Age 40
Age 50 ____ Age 60
17. What screening modality offers the greatest sensitivity and specificity and should be
recommended to those at increased risk?
___
Stool blood test
___ Stool blood test/Flexible sigmoidoscopy
Flexible sigmoidoscopy
____ Colonoscopy
Double-contrast barium enema
18. What screening modality might be best to recommend to a patient who is distrustful of
physicians or very uncomfortable with invasive procedures?
____ Stool blood test
____ Stool blood test/Flexible sigmoidoscopy
____ Flexible sigmoidoscopy
____ Colonoscopy
Double-contrast barium enema
19. Which of the following screening test(s) are recommended for a 40-year-old patient whose
65-year-old father had colorectal cancer or an adenomatous polyp?
______ Stool blood test
______ Flexible Sigmoidoscopy
______ Stool DNA testing (sDNA)
______ Colonoscopy
______ Double-contrast barium enema (DCBE)
______ All of the above
20. Which of the following screening test(s) are recommended by one or more authoritative
groups for patients at risk of hereditary non-polyposis colon cancer (HNPCC) or familial
adenomatous polyposis (FAP)? (Choose one.)
______ Stool blood test
______ Flexible Sigmoidoscopy
______ CT colonography (CTC)
______ Colonoscopy
______ Double-contrast barium enema (DCBE)
21. How often do you make colorectal cancer screening referral for eligible patients in best your
knowledge?
Very often (4)
Often (3)
Average (2)
Not often (1)
N/A (please
explain why)
The following questions are for demographic purposes:
22. What is your age?
23. What is your gender?
Female

Male

Others

75

23. What is the highest level of nursing education you have completed?
MSN
DNP
PhD
Other
24. How many years have you practiced as an APRN?
25. What is your APRN designation?
Nurse Practitioner
Nurse Anesthetist
Nurse Midwife
Clinical Nurse Specialist
26. What is your population focus?
Family
Adult (or Adult-Gero)
Acute Care
Pediatrics
Neonatology
Women’s Health
Psychiatric Mental Health
27. Please provide the type of clinical setting in which you practice.
General Practice
Family Practice
Internal Medicine
Obstetrics/ Gynecology
Gastroenterology Practice
Other (Please provide the type of your clinical setting)
28. Please indicate the State in which your practice.
Kentucky
Other
29. If in Kentucky, which county do you practice in?
30. How many hours each week do you see patients?
31. About how many patients do you see each week?
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Appendix B
Letter of Approval from Kentucky Coalition of Nurse Practitioner and Nurse Midwives

To whom it may concern:
The Kentucky Coalition of Nurse Practitioners and Nurse Midwives is in support of Yong Seon
Girdler, RN, BSN using our listserv to post a link to her survey regarding A Descriptive Study to
Examine the Relationship between APRN Knowledge and Self-Reported Referral Rates for
Colorectal Cancer Screening. As a member she has access to over 2000 members via our listserv
and internal blogs and messaging systems. We fully support her project.
Sincerely,

Leila Faucette
Executive Director
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Appendix C
SCREENING FOR COLORECTAL CANCER
CLINICAL SUMMARY OF U.S. PREVENTIVE TASK FORCE RECOMMENDATION (2008)

Screen with high sensitivity
fecal occult blood testing
(FOBT), sigmoidoscopy, or
colonoscopy.

Do not screen routinely.

Grade: A

Grade: C

Do not screen.

Grade: D

For all populations, evidence is insufficient to assess the benefits and harms of screening with
computerized tomography colonography (CTC) and fecal DNA testing.
Grade: I (insufficient evidence)

High sensitivity FOBT, sigmoidoscopy with FOBT, and colonoscopy are effective in
decreasing colorectal cancer mortality.
The risks and benefits of these screening methods vary.
Colonoscopy and flexible sigmoidoscopy (to a lesser degree) entail possible serious
complications
Intervals for recommended screening strategies.
Annual screening with high-sensitivity fecal occult blood testing.
Sigmoidoscopy every 5 years, with high-sensitivity fecal occult blood testing every 3
years.
Screening colonoscopy every 10 years.
The benefits of screening outweigh the
The likelihood that detection and early
potential harms for 50 to 75 year olds.
intervention will yield a mortality benefit
declines after age 75 because of the long
average time between adenoma
development and cancer diagnosis.
Focus on strategies that maximize the number of individuals who get screened.
Practice shared decision-making; discussions with patients should incorporate
information on test quality and availability.
Individuals with a personal history of cancer or adenomatous polyps are followed by a
surveillance regimen, and screening guidelines are not applicable.
The USPSTF recommends against the use of aspirin or nonsteroidal anti-inflammatory
drugs for the primary prevention of colorectal cancer. This recommendation is available
at www.preventiveservices.ahrq.gov

For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and
supporting documents please go to http://www.preventiveservices.ahrq.gov.
*These recommendations do not apply to individuals with specific inherited syndromes (Lynch Syndrome or Familial Adenomatous
Polyposis) or those with inflammatory bowel disease.
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